Clinical trial
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
NCT00206180 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206180 |
|---|---|
| Title | NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis |
| Official title | A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease |
| Intervention type | Drug |
| Interventions | esomeprazole magnesium (oral medication) |
| Enrollment | 120 |
| Start date | Jun 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 26, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: